Stocktoria
Allogene Therapeutics, Inc. ALLO
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-11
Allogene Therapeutics, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $156,000 | $114.1M | $0 | $0 | — | — |
| R&D expense | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | — | $151.9M |
| Operating income | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M | -$258.2M | -$202.0M | — | -$192.8M |
| Interest expense | — | — | — | — | — | $0 | $0 | — | $3.4M |
| Income tax | $0 | $443,000 | $0 | $0 | $0 | $0 | -$331,000 | — | -$117,000 |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$250.2M | -$184.6M | -$243.1M | -$211.5M |
| EPS (diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.08 | $-1.83 | — | — |
| Operating cash flow | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M | -$115.1M | -$137.3M | — | -$44.7M |
| Free cash flow | -$149.6M | -$201.0M | -$239.2M | -$225.7M | -$206.3M | -$181.1M | -$188.1M | — | -$47.9M |
| Cash & equivalents | $51.7M | $75.2M | $83.2M | $61.9M | $173.3M | $183.4M | $175.1M | $92.7M | $92.4M |
| Total assets | $415.9M | $548.7M | $642.8M | $821.6M | $1.0B | $1.2B | $717.8M | $749.4M | $773.9M |
| Total liabilities | $123.4M | $126.5M | $130.6M | $154.7M | $122.2M | $148.2M | $88.8M | $68.1M | $70.7M |
| Shareholders' equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M | $1.0B | $629.0M | $681.2M | $703.2M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | -76.8% | -39.1% | -99.9% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.